Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics, |
RCV001843481 | SCV002103062 | likely pathogenic | not provided | 2021-06-14 | criteria provided, single submitter | clinical testing | PM1, PM2, PM5, PP3 |
Centre for Population Genomics, |
RCV000133068 | SCV004232294 | pathogenic | Rett syndrome | 2024-01-11 | criteria provided, single submitter | curation | This variant has been collected from RettBASE and curated to current modified ACMG/AMP criteria. Based on the classification scheme defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like Disorders Specifications to the ACMG/AMP Variant Interpretation Guidelines VCEP 3.0, this variant is classified as pathogenic. At least the following criteria are met: This variant has been identified as a de novo occurrence in at least 2 individuals with Rett syndrome, without confirmation of paternity and maternity (PM6_Strong). (PMID: 15737703, 17089071). Has been observed in at least 5 individuals with phenotypes consistent with MECP2-related disease (PS4). (ClinVar 143535, PMID: 15737703, 16473305, 17089071, 26984561). Occurs in the well-characterized Methyl-DNA binding (MDB) functional domain of MECP2 (PM1). Computational prediction analysis tools suggests a deleterious impact (REVEL score>= 0.75) (PP3). This variant is absent from gnomAD (PM2_Supporting). |
Rett |
RCV000133068 | SCV000188056 | uncertain significance | Rett syndrome | 2006-04-24 | no assertion criteria provided | curation |